Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of +258.33% and +16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights PR Newswire ROCKVILLE, Md., Aug. 6, 2026 RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with...
PR Newswire
Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of 0.00% and -0.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights PR Newswire ROCKVILLE, Md., Aug. 3, 2026 ROCKVILLE...
PR Newswire
New Strong Sell Stocks for July 23rd
ABR, ARDX and RGNX have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2026.
Zacks
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?
Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.
Zacks
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm PR Newswire NEW YORK, July 21, 2026 NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether...
PR Newswire
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina...
PR Newswire
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants PR Newswire ROCKVILLE, Md., July 17, 2026 ROCKVILLE, Md., July 17, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today...
PR Newswire
RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff?
REGENXBIO plans to sell $100 million worth of its common stock in an underwritten public offering.
Stocktwits

Advertisement|Remove ads.